IVAX Diagnostics Presents New Laboratory Automation System at AACC Annual Meeting and Clinical Lab Exposition
IVAX Diagnostics, Inc. presented its new PARSEC(TM) instrument system at the 2004 American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Los Angeles from July 27-29. The organizers of this year’s meeting expect more companies in more booths than at any other clinical laboratory exposition in 2004 – and a new record for the Clinical Lab Expo. Organizers are inviting health care professionals to see new science and new technology in all areas of clinical diagnostics, including the areas of automation, information systems, point-of-care, OEM, and biotech.
Giorgio D’Urso, CEO and President of IVAX Diagnostics, said, “We are pleased to be presenting our new PARSEC(TM) System at this premier laboratory automation exhibition. Our new automated system is designed in a modular format and is therefore scalable to fit the testing needs of more laboratories than past instrumentation. The unique design of this system is also expected to allow for the utilization of multiple detection technologies; thus providing laboratories with an automated testing system tailored to their needs that is expected to enable them to perform more tests than traditional, dedicated instrumentation. We are very excited about offering this new instrumentation to the marketplace and believe that it will be a key factor in our future growth by allowing us to expand into additional testing sectors of the in vitro diagnostics market.”
IVAX Diagnostics also announced that additional information, including a new video presentation on the PARSEC(TM) System, is now available on its web site at http://www.ivaxdiagnostics.com .
About IVAX Diagnostics, Inc.
IVAX Diagnostics, Inc., headquartered in Miami, Florida, develops, manufactures and markets proprietary diagnostic reagents, instrumentation and software in the United States and Italy through its three subsidiaries: Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc. IVAX Corporation (AMEX:IVX) (LSE:IVX.L) owns approximately 72% of IVAX Diagnostics, Inc.
